Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic ...
In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...
Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...
Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding ...
Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage ...
A phase 1b/2 study to evaluate the safety and efficacy of igermetostat (XNW5004) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. This is an ASCO ...
The phase 1/2 ONE-SHOT study assessed a single-fraction of high-dose SBRT for early biochemical disease control and safety in ...
CHICAGO -- An investigational viral immunotherapy (CAN-2409; aglatimagene besadenovec) combined with a prodrug improved disease-free survival (DFS) when added to standard curative-intent radiotherapy ...
Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...
GREENVILLE, S.C. (WSPA) – September is Prostate Cancer Awareness Month, and doctors emphasize that early detection can save lives. Despite its prevalence, many misconceptions about the disease persist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results